The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback